The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Limitations of current Parkinson's disease therapy
Abstract
Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the "honeymoon" period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from "dopa-resistant" motor symptoms (speech impairment, abnormal posture, gait and balance problems), "dopa-resistant" nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug-related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Functional anatomy of the basal ganglia
Yelnik, J. (2002) · Movement Disorders · doi:10.1002/mds.10138 · Cited by 952
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
The Nighttime Problems of Parkinsonʼs Disease
Lees, A. J., Blackburn, N. A., & Campbell, V. L. (1988) · Clinical Neuropharmacology · doi:10.1097/00002826-198812000-00004 · Cited by 444
Functional Decline in Parkinson Disease
Jankovic, J., & Kapadia, A. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1611 · Cited by 427
Neuropathology of Autonomic Nervous System in Parkinson's Disease
Wakabayashi, K., & Takahashi, H. (1997) · European Neurology · doi:10.1159/000113469 · Cited by 407
Mayeux, R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290076015 · Cited by 383
Prevalence of orthostatic hypotension in Parkinson's disease
Senard, J. M., Rai, S., Lapeyre-Mestre, M., Brefel, C., Rascol, O., Rascol, A., & Montastruc, J. L. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.5.584 · Cited by 369
Self-citationMotor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
Mouradian, M. M., Junecos, J. L., Fabbrini, G., Schlegel, J., Bartko, J. J., & Chase, T. N. (1988) · Annals of Neurology · doi:10.1002/ana.410240304 · Cited by 360
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Ashburn, A. (2001) · Age and Ageing · doi:10.1093/ageing/30.1.47 · Cited by 330
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., & The Nomecomt Study Group* (1998) · Neurology · doi:10.1212/wnl.51.5.1309 · Cited by 326
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Self-citationEntacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients
(1997) · Annals of Neurology · doi:10.1002/ana.410420511 · Cited by 308
Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
Papa, S. M., & Chase, T. N. (1996) · Annals of Neurology · doi:10.1002/ana.410390505 · Cited by 292
Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions?
Bonnet, A.-M., Loria, Y., Saint-Hilaire, M.-H., Lhermitte, F., & Agid, Y. (1987) · Neurology · doi:10.1212/wnl.37.9.1539 · Cited by 284
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Treatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C., Koller, W., Poewe, W., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Self-citationOlanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Goetz, C. G., Blasucci, L. M., Leurgans, S., & Pappert, E. J. (2000) · Neurology · doi:10.1212/wnl.55.6.789 · Cited by 249
Freezing phenomenon in patients with parkinsonian syndromes
Giladi, N., Kao, R., & Fahn, S. (1997) · Movement Disorders · doi:10.1002/mds.870120307 · Cited by 240
Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman, L. V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J., & Chase, T. N. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1383 · Cited by 235
Murer, M. G., Dziewczapolski, G., Menalled, L. B., García, M. C., Agid, Y., Gershanik, O., & Raisman‐Vozari, R. (1998) · Annals of Neurology · doi:10.1002/ana.410430504 · Cited by 232
Clozapine in drug-induced psychosis in Parkinson's disease
(1999) · The Lancet · doi:10.1016/s0140-6736(99)00860-0 · Cited by 230
Postural instability and falls in Parkinson's disease.
Bloem, B. R., van Vugt, J. P. P., & Beckley, D. J. (2001) · PubMed · Cited by 226
Colzi, A., Turner, K., & Lees, A. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.5.573 · Cited by 225
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., & the Ropinirole Study Group* (1998) · Neurology · doi:10.1212/wnl.51.4.1057 · Cited by 223
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I
Fabbnni, G., Mouradian, M. M., Junecos, J. L., Schlegel, J., Mohr, E., & Chase, T. N. (1988) · Annals of Neurology · doi:10.1002/ana.410240303 · Cited by 214
Guttman, M., & International Pramipexole-Bromocriptine Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1060 · Cited by 209
Continuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208
Self-citationParkinson's disease: drug-induced psychiatric states.
Factor, S. A., Molho, E., Podskalny, G. D., & Brown, D. L. (1995) · PubMed · Cited by 203
Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson???s Disease
Kaakkola, S. (2000) · Drugs · doi:10.2165/00003495-200059060-00004 · Cited by 200
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
Pillon, B., Dubois, B., Cusimano, G., Bonnet, A. M., Lhermitte, F., & Agid, Y. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.2.201 · Cited by 191
Rascol, O., Brooks, D. J., Brunt, E. R., Korczyn, A. D., Poewe, W. H., & Stocchi, F. (1998) · Movement Disorders · doi:10.1002/mds.870130111 · Cited by 186
Self-citationAmantadine treatment is an independent predictor of improved survival in Parkinson's disease
Uitti, R. J., Rajput, A. H., Ahlskog, J. E., Offord, K. P., Schroeder, D. R., Ho, M. M., Prasad, M., Rajput, A., & Basran, P. (1996) · Neurology · doi:10.1212/wnl.46.6.1551 · Cited by 171
Evaluation of somnolence in Parkinson’s disease: Comparison with age- and sex-matched controls
Tan, E. K., Lum, S. Y., Fook-Chong, S. M. C., Teoh, M. L., Yih, Y., Tan, L., Tan, A., & Wong, M. C. (2002) · Neurology · doi:10.1212/wnl.58.3.465 · Cited by 169
Tolcapone and fulminant hepatitis
Assal, F., Spahr, L., Hadengue, A., Rubbici-Brandt, L., & Burkhard, P. R. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61511-5 · Cited by 167
Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Shoulson, & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430309 · Cited by 165
Biochemistry of Parkinson's disease 28 years later: A critical review
Agid, Y., Cervera, P., Hirsch, E., Javoy-Agid, F., Lehericy, S., Raisman, R., & Ruberg, M. (1989) · Movement Disorders · doi:10.1002/mds.870040514 · Cited by 163
McKeith, I. G. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.2.144 · Cited by 162
Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms
Bravi, D., Mouradian, M. M., Roberts, J. W., Davis, T. L., Sohn, Y. H., & Chase, T. N. (1994) · Annals of Neurology · doi:10.1002/ana.410360108 · Cited by 160
Stocchi, F. (2002) · Brain · doi:10.1093/brain/awf214 · Cited by 158
van Everdinge, K. J., Visser, G. H. A., Klijn, C. J. M., Kappelle, L. J., & van der Grond, J. (1998) · Annals of Neurology · doi:10.1002/ana.410440206 · Cited by 155
Dotto, P. D., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L. V., Chase, T. N., & Bonuccelli, U. (2001) · Movement Disorders · doi:10.1002/mds.1112 · Cited by 153
Influence of l -dopa and pramipexole on striatal dopamine transporter in early PD
Guttman, M., Stewart, D. E., Hussey, D., Wilson, A., Houle, S., & Kish, S. J. (2001) · Neurology · doi:10.1212/wnl.56.11.1559 · Cited by 151
Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Palmer, G. C. (2001) · Current Drug Targets · doi:10.2174/1389450013348335 · Cited by 145
Ten-year follow-up of three different initial treatments in de-novo PD
Lees, A. J., Katzenschlager, R., Head, J. A., & Ben‐Shlomo, Y. (2001) · Neurology · doi:10.1212/wnl.57.9.1687 · Cited by 143
Pallidotomy for Parkinson disease: a review of contemporary literature
Alkhani, A. M., & Lozano, A. M. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.94.1.0043 · Cited by 138
Goetz, C. G., Leurgans, S. E., & Raman, R. (2002) · Movement Disorders · doi:10.1002/mds.10024 · Cited by 135
Dopamine agonists and neuroprotection in parkinson's disease
Olanow, C. W., Jenner, P. G., & Brooks, D. J. (1998) · Annals of Neurology · doi:10.1002/ana.410440725 · Cited by 131
Orthostatic Hypotension in Patients with Parkinson??s Disease: Pathophysiology and Management
Sénard, J., Brefel‐Courbon, C., Rascol, O., & Montastruc, J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118070-00003 · Cited by 124
Self-citationSleep Disorders in Patients with Parkinson??s Disease: Epidemiology and Management
Larsen, J. P., & Tandberg, E. (2001) · CNS Drugs · doi:10.2165/00023210-200115040-00002 · Cited by 102
Pergolide monotherapy in the treatment of early PD
Barone, P., Bravi, D., Bermejo‐Pareja, F., Marconi, R., Kulisevsky, J., Malagù, S., Weiser, R., Rost, N. S., & the Pergolide Monotherapy Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.573 · Cited by 102
Apomorphine responses in parkinson's disease and the pathogenesis of motor complications
Metman, L. V., Locatelli, E. R., Bravi, D., Mouradian, M. M., & Chase, T. N. (1997) · Neurology · doi:10.1212/wnl.48.2.369 · Cited by 95
Ben‐Shlomo, Y., Churchyard, A., Head, J. A., Hurwitz, B., Overstall, P. W., Ockelford, J., & Lees, A. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1191 · Cited by 95
Surgery for Parkinson Disease: A Critical Evaluation of the State of the Art
Lang, A. E. (2000) · Archives of Neurology · doi:10.1001/archneur.57.8.1118 · Cited by 93
Levodopa Toxicity and Apoptosis
Melamed, E., Offen, D., Shirvan, A., Djaldetti, R., Barzilai, A., & Ziv, I. (1998) · Annals of Neurology · doi:10.1002/ana.410440722 · Cited by 88
Autonomic dysfunction in movement disorders
Chaudhuri, К. R. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00012 · Cited by 88
Neuroprotection by (−)-deprenyl and related compounds
Maruyama, W., & Naoi, M. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(99)00066-4 · Cited by 71
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Tan, E., & Ondo, W. G. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.729 · Cited by 70
Respiratory function in Parkinson's disease.
Shill, H. A., & Stacy, M. A. (1998) · PubMed · Cited by 56
Pain in Parkinson's disease: Common yet seldom recognized symptom is treatable
Waseem, S., & Gwinn-Hardy, K. (2001) · Postgraduate Medicine · doi:10.3810/pgm.2001.12.1063 · Cited by 54
Attempts to obtain neuroprotection in Parkinson's disease
Olanow, C. W. (1997) · Neurology · doi:10.1212/wnl.49.1_suppl_1.s26 · Cited by 47
Levodopa: why the controversy?
Agid, Y., Olanow, C. W., & Mizuno, Y. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09733-7 · Cited by 42
[Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
Dubois, B., Hauw, J., Ruberg, M., Serdaru, M., Javoy-Agid, F., & Agid, Y. (1985) · PubMed · Cited by 40
Montastruc, J., Desboeuf, K., Lapeyre‐Mestre, M., Sénard, J., Rascol, O., & Brefel‐Courbon, C. (2001) · Movement Disorders · doi:10.1002/mds.1093 · Cited by 32
Self-citationNeuroprotection for Parkinson’s disease: a new approach for a new millennium
Drukarch, B., & Muiswinkel, F. L. V. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.10.1855 · Cited by 29
Dopamine Agonists in Early Therapy for Parkinson Disease
Tanner, C. M. (2000) · JAMA · doi:10.1001/jama.284.15.1971 · Cited by 24
Disorders affecting autonomic function in parkinsonian patients.
Mathias, C. (1996) · PubMed · Cited by 20
Study design problems of DATATOP study analysis
Mäki-Ikola, O., & Heinonen, E. H. (1996) · Annals of Neurology · doi:10.1002/ana.410400624 · Cited by 7
Gonzalez-Salvador (1999) · doi:10.1002/(sici)1099-1166(199909)14:9
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
(2000) · doi:10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
Cited by
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Self-citationMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R., & Young, B. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 475
Huisman, E., Uylings, H. B. M., & Hoogland, P. V. (2004) · Movement Disorders · doi:10.1002/mds.10713 · Cited by 313
Metadata
- Authors
- Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel-Courbon, C., & Montastruc, J.-L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2003
- Volume
- 53
- Issue
- S3
- Pages
- S3-S15
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2012557172
- Cited by
- 337
- References
- 88
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.